Aashiq, M.; Silverman, D.A.; Na’ara, S.; Takahashi, H.; Amit, M.
Radioiodine-Refractory Thyroid Cancer: Molecular Basis of Redifferentiation Therapies, Management, and Novel Therapies. Cancers 2019, 11, 1382.
https://doi.org/10.3390/cancers11091382
AMA Style
Aashiq M, Silverman DA, Na’ara S, Takahashi H, Amit M.
Radioiodine-Refractory Thyroid Cancer: Molecular Basis of Redifferentiation Therapies, Management, and Novel Therapies. Cancers. 2019; 11(9):1382.
https://doi.org/10.3390/cancers11091382
Chicago/Turabian Style
Aashiq, Mohamed, Deborah A. Silverman, Shorook Na’ara, Hideaki Takahashi, and Moran Amit.
2019. "Radioiodine-Refractory Thyroid Cancer: Molecular Basis of Redifferentiation Therapies, Management, and Novel Therapies" Cancers 11, no. 9: 1382.
https://doi.org/10.3390/cancers11091382
APA Style
Aashiq, M., Silverman, D. A., Na’ara, S., Takahashi, H., & Amit, M.
(2019). Radioiodine-Refractory Thyroid Cancer: Molecular Basis of Redifferentiation Therapies, Management, and Novel Therapies. Cancers, 11(9), 1382.
https://doi.org/10.3390/cancers11091382